1. Key Insights

2. Executive Summary

3. Hemophilia A: Disease Background and Overview
3.1. Introduction
3.1.1. Sign and Symptoms of Hemophilia A
3.1.2. Inheritance Pattern of Hemophilia A
3.1.3. Molecular Pathogenesis of Hemophilia A
3.1.4. Pathophysiology of Hemophilia A
3.1.5. Risk Factors of Hemophilia A
3.2. Diagnosis of Hemophilia A
3.2.1. Establishing the Diagnosis
3.2.2. Molecular Genetic Testing
3.2.3. Screening Tests
3.2.4. Clotting Factor Tests
3.2.5. Inhibitor Testing

4. Epidemiology and Patient Population
4.1. Epidemiology Key Findings
4.2. Assumptions and Rationale: 7MM
4.3. Epidemiology Scenario: 7MM
4.3.1. Total Diagnosed Prevalence of Hemophilia A in the 7MM
4.3.2. Severity- Specific Prevalence of Hemophilia A in the 7MM
4.3.3. Prevalence of Hemophilia A with or without Inhibitors the 7MM

5. United States Epidemiology
5.1. Total Diagnosed Prevalence of Hemophilia A in the United States
5.2. Severity- Specific Prevalence of Hemophilia A in the United States
5.3. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States

6. EU-5 Country-wise Epidemiology
6.1. Germany Epidemiology
6.1.1. Total Diagnosed Prevalence of Hemophilia A in Germany
6.1.2. Severity- Specific Prevalence of Hemophilia A in Germany
6.1.3. Prevalence of Hemophilia A with or without Inhibitors in Germany
6.2. France Epidemiology
6.2.1. Total Diagnosed Prevalence of Hemophilia A in France
6.2.2. Severity- Specific Prevalence of Hemophilia A in France
6.2.3. Prevalence of Hemophilia A with or without Inhibitors in France
6.3. Italy Epidemiology
6.3.1. Total Diagnosed Prevalence of Hemophilia A and B in Italy
6.3.2. Severity-Specific Prevalence of Hemophilia A in Italy
6.3.3. Prevalence of Hemophilia A with or without Inhibitors in Italy
6.4. Spain Epidemiology
6.4.1. Total Diagnosed Prevalence of Hemophilia A in Spain
6.4.2. Severity- Specific Prevalence of Hemophilia A in Spain
6.4.3. Prevalence of Hemophilia A with Inhibitors or Without-Inhibitors in Spain
6.5. United Kingdom Epidemiology
6.5.1. Total Diagnosed Prevalence of Hemophilia A in the United Kingdom
6.5.2. Severity- Specific Prevalence of Hemophilia A in the United Kingdom
6.5.3. Prevalence of Hemophilia A with Inhibitors or Non-Inhibitors in the United Kingdom

7. Japan Epidemiology
7.1. Total Diagnosed Prevalence of Hemophilia A in Japan
7.2. Severity- Specific Prevalence of Hemophilia A in Japan
7.3. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan

8. Appendix
8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

Table 1 Summary of Hemophilia A Epidemiology (2017–2030)
Table 2 Summary of sources explored for the epidemiology of Hemophilia A
Table 3 Total Diagnosed Prevalence of HemophiliaA in the 7MM (2017–2030)
Table 4 Severity- Specific Prevalence of Hemophilia A in the 7MM (2017–2030)
Table 5 Prevalence of Hemophilia A with or without Inhibitors the 7MM (2017–2030)
Table 6 Total Diagnosed Prevalence of Hemophilia A in the United States (2017–2030)
Table 7 Severity- Specific Prevalence of Hemophilia A in the US (2017–2030)
Table 8 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States (2017–2030)
Table 9 Total Diagnosed Prevalence of Hemophilia A in Germany (2017–2030)
Table 10 Severity- Specific Prevalence of Hemophilia A in Germany (2017–2030)
Table 11 Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017–2030)
Table 12 Total Diagnosed Prevalence of Hemophilia A in France (2017–2030)
Table 13 Severity- Specific Prevalence of Hemophilia A in France (2017–2030)
Table 14 Prevalence of Hemophilia A with or Non-Inhibitors in France (2017–2030)
Table 15 Total Diagnosed Prevalence of Hemophilia A in Italy (2017–2030)
Table 16 Severity-Specific Diagnosed Prevalence of Hemophilia A in Italy (2017–2030)
Table 17 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017–2030)
Table 18 Total Diagnosed Prevalence of Hemophilia A in the Spain (2017–2030)
Table 19 Severity-Specific Prevalence of Hemophilia A in Spain (2017–2030)
Table 20 Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017–2030)
Table 21 Total Diagnosed Prevalence of Hemophilia A in the United Kingdom (2017–2030)
Table 22 Severity-Specific Prevalence of Hemophilia A in the United Kingdom (2017–2030)
Table 23 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017–2030)
Table 24 Total Diagnosed Prevalence of Hemophilia A in Japan (2017–2030)
Table 25 Severity- Specific Prevalence of Hemophilia A in Japan (2017–2030)
Table 26 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017–2030)

List of Figures
Figure 1 Coagulation Cascade and the Effects of Recombinant Activated Factor Vll (rFVlla) 
Figure 2 Inheritance Pattern of Hemophilia A 
Figure 3 Established and Proposed Risk Factors for Inhibitor Development 
Figure 4 Screening Tests for Hemophilia A 
Figure 5 Total Diagnosed Prevalence of HemophiliaA in the 7MM (2017–2030) 
Figure 6 Severity- Specific Prevalence of Hemophilia A in the 7MM (2017–2030) 
Figure 7 Prevalence of Hemophilia A with or without Inhibitors the 7MM (2017–2030) 
Figure 8 Total Diagnosed Prevalence of Hemophilia A in the United States (2017–2030) 
Figure 9 Severity- Specific Prevalence of Hemophilia A in the US (2017–2030) 
Figure 10 Prevalence of Hemophilia A with Inhibitors & Without Inhibitors in the United States (2017–2030) 
Figure 11 Total Diagnosed Prevalence of Hemophilia A in Germany (2017–2030) 
Figure 12 Severity- Specific Prevalence of Hemophilia A in Germany (2017–2030) 
Figure 13 Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017–2030) 
Figure 14 Total Diagnosed Prevalence of Hemophilia A in France (2017–2030) 
Figure 15 Severity- Specific Prevalence of Hemophilia A in France (2017–2030) 
Figure 16 Prevalence of Hemophilia A with or Non-Inhibitors in France (2017–2030) 
Figure 17 Total Diagnosed Prevalence of Hemophilia A in Italy (2017–2030) 
Figure 18 Severity-Specific Diagnosed Prevalence of Hemophilia A in Italy (2017–2030) 
Figure 19 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017–2030) 
Figure 20 Total Diagnosed Prevalence of Hemophilia A in the Spain (2017–2030) 
Figure 21 Severity-Specific Prevalence of Hemophilia A in Spain (2017–2030) 
Figure 22 Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017–2030) 
Figure 23 Total Diagnosed Prevalence of Hemophilia A in the United Kingdom (2017–2030) 
Figure 24 Severity-Specific Prevalence of Hemophilia A in the United Kingdom (2017–2030) 
Figure 25 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017–2030) 
Figure 26 Total Diagnosed Prevalence of Hemophilia A in Japan (2017–2030) 
Figure 27 Severity- Specific Prevalence of Hemophilia A in Japan (2017–2030) 
Figure 28 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017–2030)